Evidence Hub

Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics

Jin-Nong Zhang, Luqian Zhou, Yu-Qiong Yang, Wei Peng, Wen-Jing Wang, Xue-Lin Chen

The Lancet Respiratory Medicine, 2020

321 citations

Abstract

In December, 2019, numerous un­ explained pneumonia cases occurred in Wuhan, China. This outbreak was confirmed to be caused by severe acute respiratory syndrome corona virus 2 (SARS­CoV­2), belonging to the same family of viruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). The SARS epi demic in 2003 was controlled through numerous measures in China. One effect ive strategy was the establishment of fever clinics for triaging patients. Based on our first­hand experience in dealing with the present outbreak in Wuhan, we have established the following clinical strategies in adult fever clinics (figure). Patients can be afebrile in the early stages of infection, with only chills and respiratory symptoms. High temperature is not a general presentation. Elevated C­reactive protein (CRP) is an important factor of 2019 novel coronavirus disease (COVID­19; formally known as 2019­nCoV) and impaired immunity, characterised by lymphopenia, is an essential characteristic. Therefore, in afebrile patients (temperature <37·3°C) without dyspnoea, we recommend measurements of complete blood count and CRP. Subsequently, if the lymphocyte concentration is ≥1100/μL, home care with self­isolation is advised. Oral azithromycin or amoxicillin can be prescribed (measure 1, figure). Chest CT is helpful (appendix) and is more sensitive than x­ray in identifying viral pneumonia. Imaging of patients with COVID­19 initially revealed characteristic…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free